|Articles|April 22, 2014
Video Consent Proving an Obstacle in India Trials
In November 2013, India's Drug Controller General required that all clinical trials must record on video a participant's informed consent.
Advertisement
In November 2013, India's Drug Controller General required that all clinical trials must record on video a participant's informed consent, which according to a recent article, is driving recruitment rates down.
Physician investigators report the reasons patients are declining clinical trials because of the video recorded consent. Those reasons include, they believe the videos could be leaked; tampered with or misused. Also, social and religious reasons, as well as poor self image during a sickness. The physicians in the article report ranges between 10%-40% of patients declining to participate in the clinical trial after learning of the video consent requirement.
While some believe the video consent has a noble intent, the questions behind the ethics of not allowing participants the decision to opt-out of the video requirement, as well as the long-term effects on science are being debated.
Read the full story here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
Q&A: Strategies for Successful Global Clinical Trial Delivery
3
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
4
Latest NIMBLE Study Results Highlight Progress in gMG Research
5